External reference pricing in the pharmaceuticals price regulation

  • A. Kheilomskyi PrJSC «Indar», Kyiv
  • N. Datsiuk Bogomolets National Medical University, Kyiv
  • I. Zhogov PrJSC «Indar», Kyiv
  • S. Bilokobylsky PrJSC «Indar», Kyiv
Keywords: price regulation, external reference pricing, pharmaceuticals


Regulation of drug prices is an important part of regulation of the pharmaceutical market, and requires a rationalization and systematic approach. Study of the application of an external reference pricing (ERP) should be the basis for the implementation of new legislative initiatives to avoid negative consequences on the availability of essential drugs.

In order to study the experience of using ERP in different countries, learn the advantages and disadvantages of this method search and analysis of foreign literature have been made.

Analysis showed that the ERP is one of the methods of a direct price control and is widely used in the EU. The majority of the EU and the OECD countries used ERP for the price regulation of patented medicines. At the same time, the method has a number of shortcomings and difficulties in the choice of reference countries, obtaining reliable and relevant information about the prices of medicines and may have negative effect on the availability of medicines. The main components of the method are: the choice of reference countries, the calculation of the reference price, the parallel use of other approaches to determine the price. The real impact of the ERP application have not been studied enough, so international experts consider the further study of the influence ERP on the pharmaceutical market essential.

In developed countries, the price of drugs is based on multi-criteria approach, and the ERP is just one of many criteria. Effectiveness of the ERP as other methods of price regulation should be discussed in the context of healthcare system of the country, availability of drugs, physical and economic access to drugs, equitable access and rational use of drugs; the long-term prospects for the whole country as well as unexpected consequences that may occur should be considered.


1. Roemer Milton I. Health Care Costs and Financing in World Perspective // The Yale J. Biol. Med. – 1991. – N 64. – R. 435–441.
2. Seiter A. Pharmaceuticals: Cost containment, Pricing, Reimbursement // HNP Brief N 7, World Bank, 2005. – 7 r. – Available at: http://siteresources.worldbank.org/ HEALTHNUTRITIONANDPOPULATION/Resources/281627-1109774792596/HNPBrief_7.pdf
3. Pharmaceutical Legislation and Regulation. (MDS-3: Managing Access to Medicines and Health Technologies, Chapter 6), WHO, 2012 – 21 p.
4. Koncepciya rozvitku farmacevtichnogo sektoru galuzi ohoroni zdorov’ya Ukrayini na 2011–2020 roki, zatverdzhena Nakazom MOZ Ukrayini vid 13. 09. 2010 r. № 769.
5. Dacyuk. N. O., Hejlomskij O. B., Sholojko N. V. Deyaki aspekti politiki cinoregulyuvannya na likarski zasobi // Farmac. zhurn. – 2011. – № 2. – S. 23–30.
6. Bennett S., Quick J., Velasquez G. Public-Private Roles in the Pharmaceutical Sector - Implications for Equitable Access and Rational Drug Use // Health Economics and Drugs Series. – 1997. – N 005. – 115 p. – Available at: http://apps.who.int/medicinedocs/fr/d/Jwhozip27e/10.3.html#Jwhozip27e.10.3
7. Ruggeri K., Nolte E. Pharmaceutical pricing. The use of external reference pricing // RAND Corporation. – 2013. – 58 p.
8. Arzymanow B., Manning J. Value-based pricing: the wrong medicine for the nation? // 2020 health, May, 2013. – 11 p. – Available at: http://www.2020health.org/2020health/Publications/Publications-2013/-Value-based-pricing--the-wrong-medicine-for-the-nation-.html
9. Zaliska O., Mendrik O. 17-ta Svitova zustrich ISPOR – Ukrayina bere uchast // Apteka. – 2012 – № 851 (30). – Rezhim dostupu: http://www.apteka.ua/article/151525
10. Vogler S. PPRI Report. – Vienna, 2008. – 140 p. – Available at: http://ppri.oebig.at/Downloads/Publications/PPRI_Report_final.pdf
11. External reference pricing. WHO/HAI, Pharmaceutical Pricing Policies and Interventions, Policy Brief N 1. – February 2014. – Available at: http://www.haiweb.org/medicineprices/05062011/1_WHOHAI_Policy-Brief_ERP.pdf
12. Glossary for pharmaceutical policies/systems developed in the Pharmaceutical Health Information System (PHIS) Project. PHIS/AIFA/GOG, July 2009 (update April 2011). – Available at: http://whocc.goeg.at/Literaturliste/Dokumente/MethodologyTemplate/PHIS%20Glossary_UpdatedApril2011.pdf
13. Toumi M. et al. External reference pricing of medical products: simulation-based considerations for cross country coordination. Final report. // Europ. Commission, December 2013. – Available at: http://ec.europa.eu/health/healthcare/docs/erp_reimbursement_medicinal_products_en.pdf
14. Leopold C., Leopold C. et al. Differences in external price referencing in Europe: a descriptive overview // Health Policy. – 2012. – N 104 (1). – P. 50–607.
15. Bouvy J., Vogler S. Pricing and Reimbursement Policies. Update on 2004 Background Paper, BP 8.3 // WHO, 2013. – Available at: http://www.who.int/medicines/areas/priority_medicines/BP8_3_pricing.pdf
16. Carone G., Schwierz C., Xavier A. Cost-containment policies in public pharmaceutical spending in the EU. // Europ. Commission, Directorate General for Economic and Financial Affairs, 2012. – Available at: http://ec.europa.eu/economy_finance/publications/economic_paper/2012/pdf/ecp_461_en.pdf
17. Espin J., Rovira J., Olry de Labry A. WHO/HAI Project on Medicine Prices and Availability Review Series on Pharmaceutical Pricing Policies and Interventions Working Paper 1: External Reference Pricing // WHO, May 2011. – Available at: http://www.haiweb.org/medicineprices/05062011/ERP%20final%20May2011.pdf
18. External Reference Pricing. Europe Economics July 2013. – Available at: http://www.europe-economics.com/publications/external_reference_pricing_-_final_report.pdf
19. Zaliska O. M., Parnovskij B. L., Mudrak I. G. Farmakoekonomika: terminologiya, metodi i zakonodavchi vimogi do farmakoekonomichnogo analizu u providnih krayinah svitu // Racionalnaya farmakoterapiya. – 2008. – № 1 (6). – Rezhim dostupu: http://rpht.com.ua/article/78.html
20. Ulrich Kaiser, Susan J. Mendez, Thomas Ronde, Hannes Ullrich. Regulation of Pharmaceutical Prices: Evidence from a Reference Price Reform in Denmark // IZA Discussion Paper N. 7248, February 2013. – Available at: http://ftp.iza.org/dp7248
How to Cite
Kheilomskyi, A., Datsiuk, N., Zhogov, I., & Bilokobylsky, S. (2019). External reference pricing in the pharmaceuticals price regulation. Farmatsevtychnyi Zhurnal, (6), 23-28. Retrieved from https://pharmj.org.ua/index.php/journal/article/view/269
Management of pharmacy